Galapagos Subsidiary BioFocus Collaborate with Senexis
Complete the form below to unlock access to ALL audio articles.
Senexis Limited and Galapagos NV have announced that they have expanded their collaboration to optimise Senexis' inhibitors of amyloid-induced toxicity and neuroinflammation for the treatment of Alzheimer's disease.
Galapagos will receive research fees for the medicinal chemistry services provided to Senexis.
The collaboration aims to significantly advance Senexis' small molecule Alzheimer's programs towards the clinic and is unrelated to Galapagos' own Alzheimer's disease targets program.
"We are delighted to continue our successful collaboration with BioFocus," said David Scopes, Senexis' Chief Scientific Officer.
"We have now made significant progress with our small molecule programmes, so that our lead series now demonstrate similar potency to peptides when inhibiting amyloid-induced toxicity."
Onno van de Stolpe, Galapagos' CEO, commented, "We are pleased that BioFocus has been able to help advance Senexis' Alzheimer's program, and offering our medicinal chemistry expertise should further help to accelerate their development program."
